THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [*] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASSET PURCHASE AGREEMENT By and between Amylin...Asset Purchase Agreement • March 2nd, 2015 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
ASSET PURCHASE AGREEMENT (this “Agreement”) is made and executed as of November 5, 2014 (the “Execution Date”), by and between Amylin Pharmaceuticals, LLC, a Delaware limited liability company (“Amylin” or “Seller”), solely for purposes of Sections 2.1.1, 2.2.1 and 2.3.2, AstraZeneca Pharmaceuticals LP, a Delaware limited partnership (“AZPLP”, and, together with Amylin but solely for purposes of Sections 2.1.1, 2.2.1 and 2.3.2, “Seller”), and Aegerion Pharmaceuticals, Inc., a Delaware corporation (“Buyer”). Amylin and Buyer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [*] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE AGREEMENT BETWEEN SHIONOGI & CO., LTD. AND...License Agreement • March 2nd, 2015 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [*] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FIFTH LOAN MODIFICATION AGREEMENTLoan Modification Agreement • March 2nd, 2015 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
This Fifth Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of January 9, 2015, by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and AEGERION PHARMACEUTICALS, INC., a Delaware corporation with its chief executive office located at One Main Street, 8th Floor, Cambridge, Massachusetts 02142 (“Borrower”).
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [*] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE AGREEMENT BY AND BETWEEN AMGEN INC. AND...License Agreement • March 2nd, 2015 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This License Agreement (this “Agreement”) is made effective as of the 7th day of February, 2006 (the “Effective Date”) by and between Amgen Inc., a Delaware corporation with a principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320- 1799 (“Amgen”), and Amylin Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 9360 Towne Centre Drive, Ste. 110, San Diego, California 92121 (“Amylin”). Amgen and Amylin are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 2nd, 2015 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
This First Amendment (this “Amendment”) dated as of January 9, 2015 (the “Execution Date”) is to the Asset Purchase Agreement, dated as of November 5, 2014 (the “Agreement”), by and among Amylin Pharmaceuticals, LLC, a Delaware limited liability company (“Amylin” or “Seller”), AstraZeneca Pharmaceuticals LP, a Delaware limited partnership (solely for purposes of Sections 2.1.1, 2.2.1 and 2.3.2 of the Agreement) (“AZPLP”, and, together with Amylin but solely for purposes of Sections 2.1.1, 2.2.1 and 2.3.2 of the Agreement, “Seller”), and Aegerion Pharmaceuticals, Inc., a Delaware corporation (“Buyer”). Unless otherwise specifically provided herein, capitalized terms used, but not otherwise defined, herein shall have the meanings ascribed thereto in the Agreement.
